Zeria Pharmaceutical Co., Ltd.

TSE:4559.T

2375 (JPY) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

2023202220212020201920182017201620152014201320122011201020092008200720062005
Revenue 75,725.07568,383.22759,532.82955,431.72560,435.2361,823.7664,577.69964,860.18162,479.0361,060.95461,991.88153,324.98453,194.48749,514.36450,761.80947,669.52849,756.75452,765.30755,564.507
Cost of Revenue 25,543.75118,894.62717,384.57715,796.87916,643.61317,752.65518,341.8918,168.98117,930.38218,521.13418,347.6717,596.60918,547.52318,442.30123,300.75422,257.19922,535.6524,137.35226,800.664
Gross Profit 50,181.32449,488.642,148.25239,634.84643,791.61744,071.10546,235.80946,691.244,548.64842,539.8243,644.21135,728.37534,646.96431,072.06327,461.05525,412.32927,221.10428,627.95528,763.843
Gross Profit Ratio 0.6630.7240.7080.7150.7250.7130.7160.720.7130.6970.7040.670.6510.6280.5410.5330.5470.5430.518
Reseach & Development Expenses 3,726.9193,4564,7895,4116,3426,8327,331.9148,458.878,579.4179,8827,4645,6290000000
General & Administrative Expenses 31,447.75928,26727,44725,43327,56027,66728,253.49528,168.74726,305.47625,08424,37022,0700000000
Selling & Marketing Expenses 5,2904,3793,5465,3485,8795,8355,8205,5225,0984,8955,0203,4180000000
SG&A 36,737.75932,64630,99330,78133,43933,50234,073.49533,690.74731,403.47629,97929,39025,4880000000
Other Expenses 169.36221.7835.58538.65236.94429.21669.9857.83796.24485.64516.67248.67182.758215.452209.128177.158131.32843.60812.585
Operating Expenses 40,464.67840,473.62635,782.19236,192.76839,696.79340,334.03741,405.40942,149.61739,982.89239,861.14936,854.1331,117.12730,078.19827,760.61425,876.91824,087.74524,660.98925,189.60726,819.514
Operating Income 9,716.6469,014.9736,366.0583,442.0764,094.8243,737.0674,830.3994,541.5824,565.7552,678.676,790.084,611.2474,568.7663,311.4491,584.1371,324.5842,560.1153,438.3481,944.329
Operating Income Ratio 0.1280.1320.1070.0620.0680.060.0750.070.0730.0440.110.0860.0860.0670.0310.0280.0510.0650.035
Total Other Income Expenses Net -208.252-1,745-646478-901,482746.871379.251696.3051,141.27519.2291,412.659112.483-548.465-15.57679.376216.506157.181287.492
Income Before Tax 9,508.3947,272.6985,721.7643,922.9053,920.2775,221.0145,577.2714,920.8345,262.0613,819.9417,309.316,023.9074,681.2492,762.9841,568.5672,003.962,776.6213,595.5292,231.821
Income Before Tax Ratio 0.1260.1060.0960.0710.0650.0840.0860.0760.0840.0630.1180.1130.0880.0560.0310.0420.0560.0680.04
Income Tax Expense 1,813.1851,065.8871,746.969791.409981.4671,757.2081,394.2451,344.9531,729.7911,262.2952,034.892,026.3611,765.04928.671566.79800.8211,137.5231,527.34983.057
Net Income 7,731.2626,195.8653,961.1843,143.1252,925.3753,454.0984,157.813,544.3593,513.4962,557.6465,277.083,982.2262,861.0171,842.6951,001.7761,203.1391,639.0982,068.1881,248.763
Net Income Ratio 0.1020.0910.0670.0570.0480.0560.0640.0550.0560.0420.0850.0750.0540.0370.020.0250.0330.0390.022
EPS 175.39140.2687.7668.2262.6269.5680.7266.7366.1548.15115.0187.5762.940.522.0126.2835.5944.5126.57
EPS Diluted 175.39140.2687.7668.2262.6269.5680.7266.7366.1548.15115.0187.5762.940.522.0126.2835.5944.5126.57
EBITDA 17,272.09614,06511,651.6547,849.2668,137.4227,229.3919,124.4698,500.1027,859.2085,682.1539,671.6637,801.3397,877.1476,234.8164,239.4843,740.5674,775.6835,140.0133,407.453
EBITDA Ratio 0.2280.2060.1960.1420.1350.1170.1410.1310.1260.0930.1560.1460.1480.1260.0840.0780.0960.0970.061